Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: AI image
India has administered more than 1 crore doses of the human papillomavirus (HPV) vaccine in less than nine months since it launched its nationwide vaccination campaign.
This means the country has covered nearly 87% of its annual target cohort of 14-year-old girls. The milestone marks a major step towards preventing cervical cancer, which is largely caused by repeated HPV infections.
According to the Ministry of Health and Family Welfare, the campaign has reached nearly 87% of its estimated annual target of 1.2 crore girls, based on 2021 population estimates from the Registrar General of India.
The vaccination drive was started in February 2026 and provides free, voluntary single-dose HPV vaccination to eligible 14-year-old girls at designated government health facilities.
Six states, Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar, have reported 100% coverage of their target populations.
Among other states, Assam has recorded 95.63% coverage, followed by Telangana at 95.28%, Karnataka at 93.16% and Uttarakhand at 90.17%. Chhattisgarh and Rajasthan have crossed 80% coverage, while Kerala, Tamil Nadu and Odisha have achieved more than 70%.
In terms of the number of girls vaccinated, Uttar Pradesh leads with more than 29.33 lakh, followed by Bihar with 13.70 lakh and Gujarat with 7.75 lakh.
Also read: Menstrual Blood-Based Self-Sampling Cervical Cancer Test Gets Patent-Know Everything About It
Almost all cervical cancer cases are caused by repeated infection with high-risk types of human papillomavirus, a common virus transmitted through sexual contact.
Most HPV infections clear naturally without causing health problems. The progression from HPV infection to cervical cancer generally takes 15–20 years, but it can happen faster in women with weakened immune systems.
HPV vaccination helps prevent infections caused by HPV types that cause cancer before exposure to the virus. Vaccinating girls at age 14 aims to provide protection before they are likely to encounter HPV. The vaccine is a preventive intervention. It does not treat an existing HPV infection or cervical cancer.
Also read: About 7.9% Of Women In Kerala Are Affected By Cervical Cancer; Why Early Detection Is Important
The government says the campaign's progress has been supported by coordination between the Centre, state governments, district administrations, healthcare professionals and frontline workers, including ASHAs and ANMs.
The U-WIN digital platform is being used for beneficiary tracking, monitoring vaccination coverage, maintaining digital records and identifying eligible girls yet to receive the vaccine. Parents can also use the platform to book vaccination slots and obtain digital certificates.
Vaccination sessions are conducted at designated government health facilities under the supervision of trained medical officers. Arrangements have also been made for identifying and managing adverse events after vaccination.
Cervical cancer remains a major public health concern in India, despite being largely preventable through HPV vaccination.
The World Health Organization's cervical cancer elimination strategy aims for 90% of girls to be fully vaccinated against HPV by age 15, 70% of women to undergo screening by ages 35 and 45, and 90% of women diagnosed with cervical disease to receive appropriate treatment.
Cervical cancer prevention entails HPV vaccination, regular screening and timely treatment of precancerous changes.
Credit: AI image
In what can be described as a major breakthrough, a new treatment combination has shown tremendous promise in advanced pancreatic cancer treatment. A recent early-stage clinical trial showed that the combo shrank tumours in more than 60% of patients and controlled disease progression in 90% of patients.
The findings raise hope for pancreatic cancer, which is often diagnosed late as well as has limited treatment options. Despite positive outcomes, larger trials are needed to establish how much the treatment improves survival.
Also read: Experimental Vaccine For Blood Cancer Cuts Death Risk By 41% In Trial: How Does It Work?
The combination includes daraxonrasib, an experimental targeted cancer drug, alongside two chemotherapy medicines, gemcitabine and nab-paclitaxel.
The updated results from the Phase 1/2 RMC-GI-102 trial were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
The study involved 61 patients with metastatic pancreatic adenocarcinoma who had not previously received treatment for their metastatic disease. Participants received the combination and were followed for a median of 18.3 months.
A 90.2% control in disease was reported, meaning the cancer either shrank or remained stable. The objective response rate, which measures tumours that shrank significantly or disappeared, was 60.7%. This included complete responses in 8.2% of patients, whose tumours were no longer detected.
Median progression-free survival was 12.8 months, meaning patients lived a median of nearly 13 months without their cancer progressing or dying. The estimated proportion of patients alive at one year was 76.6%.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings, said “this is the closest to cure”. He also said that he had never seen so many tumours disappear in patients whose cancer had spread.
He also said, “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival."
He added, “The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Daraxonrasib, also known as RASONQUE, targets RAS, which drives cell growth. Mutations in RAS, especially KRAS, can keep these growth signals on, allowing pancreatic cancer cells to multiply uncontrollably.
The drug is designed to inhibit active RAS proteins and disrupt the signals that cancer cells depend on for growth and survival. Researchers are combining it with chemotherapy to attack the cancer through different mechanisms.
Gemcitabine interferes with cancer cell DNA synthesis, while nab-paclitaxel disrupts microtubules, structures essential for cell division. Combining these drugs with targeted RAS inhibition could produce more sustained responses.
Pancreatic cancer remains one of the most difficult cancers to treat once it has spread beyond the pancreas. Many patients are diagnosed at an advanced stage, when surgery may no longer be possible.
The RAS signalling mechanism has long been considered a challenging target for cancer treatment. The development of drugs capable of fighting this has therefore opened a new avenue of research, especially pancreatic cancers driven by RAS mutations.
The trial's response rates and duration of disease control are encouraging. However, it was a small, open-label study without a chemotherapy comparison group.
Researchers cannot determine yet how much of the benefit came from daraxonrasib rather than chemotherapy or whether the combination will significantly extend survival.
Daraxonrasib is being investigated in larger clinical trials to determine its effectiveness and safety. A Phase 3 trial, RASolute 303, is comparing daraxonrasib alone, daraxonrasib combined with gemcitabine and nab-paclitaxel, and chemotherapy alone in patients with previously untreated metastatic pancreatic cancer.
These results will help establish whether the promising early findings translate into a meaningful improvement in survival and whether the combination could become a new treatment option.
Credit: iStock
The World Health Organization (WHO) has designated COVID-19 variant PJ.2.1, a descendant of the JN.1 lineage with 24 spike protein changes, as a Variant Under Monitoring (VUM). As of November 8, the variant had been detected in 18 countries, with its share of reported sequences increasing particularly in Canada and the United States.
"Considering the available evidence, the additional public health risk posed by PJ.2.1 is evaluated as low at the global level, with low confidence," the WHO said in its initial risk evaluation published by its Technical Advisory Group on Virus Evolution (TAG-VE).
Laboratory findings suggest that the variant does not show substantial additional antibody escape compared with other circulating variants. Blood samples from recipients of LP.8.1- and XFG-adapted vaccines were also able to neutralize it in laboratory tests.
However, there is insufficient clinical data to determine whether PJ.2.1 causes more severe illness.
Also read: New COVID Variant PJ.2.1 Spreading Globally: Is India At Risk, Are There New Symptoms?
According to the WHO report, "PJ.2.1 is a highly mutated variant with 24 amino acid differences in the Spike protein alone."
First identified in Canada, laboratory studies indicate that it binds more strongly to human ACE2 receptors, which the virus uses to enter cells. However, stronger receptor binding does not necessarily mean faster transmission between people.
The WHO noted that increased receptor binding "may contribute to the observed growth, but do not directly establish increased transmissibility in humans."
The proportion of PJ.2.1 among available global sequences increased from 1% in epidemiological week 33 to 11.6% in week 41, according to the WHO.
As of November 8, 2026, 722 sequences had been submitted to the GISAID, an open access database, from 18 countries.
Read More: New COVID-19 Variant PJ.2.1 Spreads Globally: WHO Says Symptoms Resemble Cold, Flu
In a study involving plasma from 36 recipients of an LP.8.1-adapted vaccine, researchers found no greater antibody evasion against PJ.2.1 than against most tested variants.
Another study involving 22 participants found that neutralisation titres against PJ.2.1 increased 2.8-fold, from 228 before vaccination to 642, at a median of 14 days after an XFG-adapted mRNA vaccine.
These findings suggest that vaccine-induced antibodies can neutralize PJ.2.1 in laboratory tests. However, they do not establish real-world vaccine effectiveness against infection or severe disease, the WHO report said.
"There is currently no evidence establishing greater disease severity associated with PJ.2.1, although comparative clinical data remain limited," the WHO said.
The agency has called for further studies to assess vaccine effectiveness, compare hospitalisations and severe disease outcomes, evaluate antiviral susceptibility and strengthen genomic surveillance.
Dr Gopakumar, Senior Consultant and Head of the Department of Internal Medicine at Apollo Adlux Hospital, Kerala, said the number of mutations alone does not determine how dangerous a variant is.
"The emergence of the new COVID-19 variant PJ.2.1 highlights the virus’s continued ability to evolve. While the reported 24 mutations, particularly in the spike protein, have attracted attention, the number of mutations alone does not determine how dangerous a variant is. What matters clinically is whether these changes make the virus more transmissible, help it evade existing immunity or increase the risk of severe illness," he told HealthandMe.
Dr Navneet Sood, Associate Director and Senior Consultant, Pulmonology, Dharamshila Narayana Superspeciality Hospital, Delhi, added that current evidence does not indicate an increased impact on disease severity compared with previous variants.
"While it is safe to say that the evidence currently shows that there is no increased impact of PJ.2.1 compared to previous variants in disease severity, the WHO's variant surveillance system is still monitoring the potential for new variants to emerge and experts have emphasized the need for genomic monitoring. Public awareness should be centred on identifying respiratory symptoms, testing if required, and taking additional precautions for vulnerable people," he told HealthandMe.
The WHO currently assesses the additional global public health risk from PJ.2.1 as low, although confidence in this assessment remains limited.
There is no need to panic, but experts advise people to remain vigilant. Older adults, immunocompromised individuals and those with chronic illnesses should take particular care. Maintaining respiratory hygiene, ensuring adequate ventilation and seeking medical advice if respiratory symptoms develop remain sensible precautions.
© $2026 Times Horizon Private Limited